Healios Expects To Take Regenerative Medicine Lead in 2018
This article was originally published in PharmAsia News
Healios President Tadashisa Kagimoto said he expects to move a macular-degeneration regenerative-medicine treatment out of early-stage clinical trials to its joint venture with Dainippon Sumitomo Pharma to take it through the next stage of trials.
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.